-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Viking Therapeutics, Lowers Price Target to $102

Benzinga·04/24/2025 17:05:54
Listen to the news
Morgan Stanley analyst Michael Ulz maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target from $105 to $102.